02916nam 22006615 450 991029832470332120200706210448.03-319-00978-810.1007/978-3-319-00978-0(CKB)2550000001166534(EBL)1592324(OCoLC)897576910(SSID)ssj0001066480(PQKBManifestationID)11585485(PQKBTitleCode)TC0001066480(PQKBWorkID)11067048(PQKB)10347637(MiAaPQ)EBC1592324(DE-He213)978-3-319-00978-0(PPN)176103503(EXLCZ)99255000000116653420131107d2014 u| 0engur|n|---|||||txtccrMolecular Vaccines From Prophylaxis to Therapy - Volume 2 /edited by Matthias Giese1st ed. 2014.Cham :Springer International Publishing :Imprint: Springer,2014.1 online resource (434 p.)Description based upon print version of record.3-319-00977-X 1-306-16576-8 Includes bibliographical references and index.Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.VaccinesImmunologyMolecular biologyVaccinehttps://scigraph.springernature.com/ontologies/product-market-codes/B16010Immunologyhttps://scigraph.springernature.com/ontologies/product-market-codes/B14000Molecular Medicinehttps://scigraph.springernature.com/ontologies/product-market-codes/B1700XVaccines.Immunology.Molecular biology.Vaccine.Immunology.Molecular Medicine.610611.01816615.372615372Giese Matthiasedthttp://id.loc.gov/vocabulary/relators/edtBOOK9910298324703321Molecular Vaccines2537239UNINA